Journal
AMINO ACIDS
Volume 48, Issue 8, Pages 1877-1895Publisher
SPRINGER WIEN
DOI: 10.1007/s00726-016-2189-0
Keywords
Brain; Creatine; Guanidinoacetate; Blood brain barrier; Creatine deficiency syndromes; AGAT; GAMT; SLC6A8
Categories
Funding
- Swiss National Science Foundation [3100A0-116859, 31003A-130278]
- Swiss National Science Foundation (SNF) [31003A_130278] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
While it has long been thought that most of cerebral creatine is of peripheral origin, the last 20 years has provided evidence that the creatine synthetic pathway (AGAT and GAMT enzymes) is expressed in the brain together with the creatine transporter (SLC6A8). It has also been shown that SLC6A8 is expressed by microcapillary endothelial cells at the blood-brain barrier, but is absent from surrounding astrocytes, raising the concept that the blood-brain barrier has a limited permeability for peripheral creatine. The first creatine deficiency syndrome in humans was also discovered 20 years ago (GAMT deficiency), followed later by AGAT and SLC6A8 deficiencies, all three diseases being characterized by creatine deficiency in the CNS and essentially affecting the brain. By reviewing the numerous and latest experimental studies addressing creatine transport and synthesis in the CNS, as well as the clinical and biochemical characteristics of creatine-deficient patients, our aim was to delineate a clearer view of the roles of the blood-brain and blood-cerebrospinal fluid barriers in the transport of creatine and guanidinoacetate between periphery and CNS, and on the intracerebral synthesis and transport of creatine. This review also addresses the question of guanidinoacetate toxicity for brain cells, as probably found under GAMT deficiency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available